Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cisplatin and the sensitive cell

Nature Medicine volume 9, pages 513–514 (2003)Cite this article

Epigenetic suppression of FANCF, a member of the Fanconi anemia gene family, is now implicated in some ovarian cancers. Might this suppression explain the sensitivity of such cancers to the cross-linking agent cisplatin (pages 568–574)?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Damage control.

Kimberly Homer

References

  1. Taniguchi, T. et al. Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors. Nat. Med. 9, 568–574 (2003).

    Article  CAS  Google Scholar 

  2. D'Andrea, A.D. & Grompe, M. The Fanconi anaemia/BRCA pathway. Nat. Rev. Cancer 3, 23–34 (2003).

    Article  CAS  Google Scholar 

  3. Bagby, G.C. Genetic basis of Fanconi anemia. Curr. Opin. Hematol. 10, 68–76 (2003).

    Article  CAS  Google Scholar 

  4. Lensch, M.W. et al. Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemia. Blood (in the press).

  5. Nakanishi, K. et al. Interaction of FANCD2 and NBS1 in the DNA damage response. Nat. Cell Biol. 4, 913–920 (2002).

    Article  CAS  Google Scholar 

  6. Howlett, N.G. et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297, 606–609 (2002).

    Article  CAS  Google Scholar 

  7. Pellegrini, L. et al. Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature 420, 287–293 (2002).

    Article  CAS  Google Scholar 

  8. Pang, Q. et al. The anti-apoptotic function of Hsp70 in the interferon inducible double-stranded RNA-dependent protein kinase-mediated death signaling pathway requires the Fanconi anemia protein, FANCC. J. Biol. Chem. 277, 49638–49643 (2002)

    Article  CAS  Google Scholar 

  9. Shimamura, A. et al. A novel diagnostic screen for defects in the Fanconi anemia pathway. Blood 100, 4649–4654 (2002).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. OSHU Cancer Institute, School of Medicine, Oregon Health and Science University, Portland, Oregon, USA

    Grover C. Bagby & Susan B. Olson

  2. Grover C. Bagby & Susan B. Olson

Authors
  1. Grover C. Bagby
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan B. Olson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bagby, G., Olson, S. Cisplatin and the sensitive cell. Nat Med 9, 513–514 (2003). https://doi.org/10.1038/nm0503-513

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0503-513

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing